Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
dc.contributor.author | Corrie, P | |
dc.contributor.author | Marshall, A | |
dc.contributor.author | Dunn, J | |
dc.contributor.author | Middleton, M | |
dc.contributor.author | Nathan, P | |
dc.contributor.author | Gore, M | |
dc.contributor.author | Davidson, N | |
dc.contributor.author | Nicholson, S | |
dc.contributor.author | Kelly, C | |
dc.contributor.author | Marples, M | |
dc.contributor.author | Danson, S | |
dc.contributor.author | Marshall, E | |
dc.contributor.author | Houston, S | |
dc.contributor.author | Board, R | |
dc.contributor.author | Waterston, A | |
dc.contributor.author | Nobes, J | |
dc.contributor.author | Harries, M | |
dc.contributor.author | Kumar, S | |
dc.contributor.author | Young, G | |
dc.contributor.author | Lorigan, Paul C | |
dc.date.accessioned | 2014-06-11T08:21:26Z | |
dc.date.available | 2014-06-11T08:21:26Z | |
dc.date.issued | 2014-05 | |
dc.identifier.citation | Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. 2014, 15 (6):620-30 Lancet Oncol | en |
dc.identifier.issn | 1474-5488 | |
dc.identifier.pmid | 24745696 | |
dc.identifier.doi | 10.1016/S1470-2045(14)70110-X | |
dc.identifier.uri | http://hdl.handle.net/10541/320613 | |
dc.description.abstract | Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of recurrence. We report results from the preplanned interim analysis. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to The lancet oncology | en |
dc.title | Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. | en |
dc.type | Article | en |
dc.contributor.department | Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK. | en |
dc.identifier.journal | The Lancet Oncology | en |
html.description.abstract | Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of recurrence. We report results from the preplanned interim analysis. |